Meyka Pro banner
LifeMD, Inc.

LifeMD, Inc. (NASDAQ: LFMDP) Stock Competitors & Peer Comparison

See LFMDP's competitors and their performance on the NASDAQ and across the wider stock market.

LFMDPNASDAQ
HealthcareMedical - Pharmaceuticals
$23.17
$0.005(0.02%)
U.S. Market opens in 58h 32m

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for LFMDP and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
LFMDP$23.23-0.43%158.9M-718.03-$0.03N/A
RPRX$61.45-0.45%26.9B11.54$5.25+1.52%
CORT$121.29+1.90%13.1B345.86$0.35N/A
WBA$11.98+0.50%10.4B-1.64-$7.29+4.17%
LQDA$68.53-9.03%6.3B507.50$0.14N/A
KNSA$79.37-1.77%6B87.19$0.90N/A
TRLV$10.91+8.13%1.7B-24.40-$0.42N/A
HROWL$25.61+0.19%1.4BN/AN/AN/A
HROWM$26.03-0.08%1.3BN/AN/AN/A
LTGO$21.74+3.82%1.3BN/AN/AN/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Royalty Pharma plc (NASDAQ: RPRX)

LFMDP vs RPRX Comparison August 2026

LifeMD, Inc. (NASDAQ: LFMDP) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LFMDP stands at 158.9M. In comparison, RPRX has a market cap of 26.9B. Regarding current trading prices, LFMDP is priced at $23.23 on the NASDAQ, while RPRX trades at $61.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LFMDP currently has a P/E ratio of -718.03, whereas RPRX's P/E ratio is 11.54. In terms of profitability, LFMDP's ROE is -1.79%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, LFMDP is less volatile compared to RPRX. This indicates lower risk in terms of short-term price fluctuations for LFMDP.Check RPRX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions